申请人:BORAGEN INC
公开号:WO2021061823A1
公开(公告)日:2021-04-01
The present disclosure describes novel compounds, or their pharmaceutically acceptable salts, pharmaceutical compositions containing them, and their medical uses. The compounds of the disclosure have activity as Janus kinase (JAK) inhibitors and are useful in the treatment or control of inflammation, auto-immune diseases, cancer, and other disorders and indications where modulation of JAK would be desirable. Also described herein are methods of treating inflammation, auto-immune diseases, cancer, and other conditions susceptible to inhibition of JAK by administering a compound herein described.
本公开描述了新颖化合物或其药用盐、含有它们的药物组合物以及它们的医药用途。本公开的化合物具有作为Janus激酶(JAK)抑制剂的活性,并且在治疗或控制炎症、自身免疫疾病、癌症以及其他需要调节JAK的紊乱和适应症方面是有用的。本文还描述了通过给予本文描述的化合物来治疗炎症、自身免疫疾病、癌症以及其他容易受到JAK抑制影响的疾病的方法。